Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human APOBEC3B promotes tumor heterogeneity in vivo including signature mutations and metastases.
Durfee C, Temiz NA, Levin-Klein R, Argyris PP, Alsøe L, Carracedo S, de la Vega AA, Proehl J, Holzhauer AM, Seeman ZJ, Lin YT, Vogel RI, Sotillo R, Nilsen H, Harris RS. Durfee C, et al. Among authors: argyris pp. bioRxiv [Preprint]. 2023 Feb 25:2023.02.24.529970. doi: 10.1101/2023.02.24.529970. bioRxiv. 2023. Update in: Cell Rep Med. 2023 Oct 17;4(10):101211. doi: 10.1016/j.xcrm.2023.101211. PMID: 36865194 Free PMC article. Updated. Preprint.
The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
Serebrenik AA, Argyris PP, Jarvis MC, Brown WL, Bazzaro M, Vogel RI, Erickson BK, Lee SH, Goergen KM, Maurer MJ, Heinzen EP, Oberg AL, Huang Y, Hou X, Weroha SJ, Kaufmann SH, Harris RS. Serebrenik AA, et al. Among authors: argyris pp. Clin Cancer Res. 2020 Jul 1;26(13):3397-3407. doi: 10.1158/1078-0432.CCR-19-2786. Epub 2020 Feb 14. Clin Cancer Res. 2020. PMID: 32060098 Free PMC article.
APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
Law EK, Levin-Klein R, Jarvis MC, Kim H, Argyris PP, Carpenter MA, Starrett GJ, Temiz NA, Larson LK, Durfee C, Burns MB, Vogel RI, Stavrou S, Aguilera AN, Wagner S, Largaespada DA, Starr TK, Ross SR, Harris RS. Law EK, et al. Among authors: argyris pp. J Exp Med. 2020 Dec 7;217(12):e20200261. doi: 10.1084/jem.20200261. J Exp Med. 2020. PMID: 32870257 Free PMC article.
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.
Boumelha J, de Carné Trécesson S, Law EK, Romero-Clavijo P, Coelho MA, Ng KW, Mugarza E, Moore C, Rana S, Caswell DR, Murillo M, Hancock DC, Argyris PP, Brown WL, Durfee C, Larson LK, Vogel RI, Suárez-Bonnet A, Priestnall SL, East P, Ross SJ, Kassiotis G, Molina-Arcas M, Swanton C, Harris R, Downward J. Boumelha J, et al. Among authors: argyris pp. Cancer Res. 2022 Oct 4;82(19):3435-3448. doi: 10.1158/0008-5472.CAN-22-0325. Cancer Res. 2022. PMID: 35930804 Free PMC article.
DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo.
Naumann JA, Argyris PP, Carpenter MA, Gupta HB, Chen Y, Temiz NA, Zhou Y, Durfee C, Proehl J, Koniar BL, Conticello SG, Largaespada DA, Brown WL, Aihara H, Vogel RI, Harris RS. Naumann JA, et al. Among authors: argyris pp. Int J Mol Sci. 2023 May 26;24(11):9305. doi: 10.3390/ijms24119305. Int J Mol Sci. 2023. PMID: 37298259 Free PMC article.
Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases.
Durfee C, Temiz NA, Levin-Klein R, Argyris PP, Alsøe L, Carracedo S, Alonso de la Vega A, Proehl J, Holzhauer AM, Seeman ZJ, Liu X, Lin YT, Vogel RI, Sotillo R, Nilsen H, Harris RS. Durfee C, et al. Among authors: argyris pp. Cell Rep Med. 2023 Oct 17;4(10):101211. doi: 10.1016/j.xcrm.2023.101211. Epub 2023 Oct 4. Cell Rep Med. 2023. PMID: 37797615 Free PMC article.
60 results